Rajvir Madan Joins Arcutis as Chief Digital and Information Officer
June 01 2021 - 7:30AM
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage
biopharmaceutical company focused on developing and commercializing
treatments for unmet needs in immune-mediated dermatological
diseases and conditions, or immuno-dermatology, today announced
that Rajvir (Raj) Madan has joined the company as its first Chief
Digital and Information Officer. In this role, Mr. Madan will be
responsible for providing the vision, strategic direction and
overall leadership of digital, data/analytics and information
technology initiatives across Arcutis.
“We are thrilled to welcome Raj to our executive
team. He brings deep expertise in digital and technology
transformation in the healthcare sector, and under his guidance,
Arcutis will look to evolve our digital and analytics capabilities
to transform critical business areas as we move toward our first
potential commercial launch,” said Frank Watanabe, Arcutis’
President and Chief Executive Officer. “We look forward to working
with Raj and are excited to leverage his expertise in support of
our efforts to elevate the standard of care for dermatological
diseases through digital and technology innovations.”
“I am excited to join Arcutis, with its bold vision to address
unmet patient needs in the medical dermatology sector,” said Mr.
Madan. “Arcutis’ commitment to transforming their digital and data
capabilities to drive value across their various platforms makes
this an amazing opportunity, and I look forward to contributing to
the company’s continued growth.”
Mr. Madan brings over 20 years of digital transformation and
innovation experience to the Arcutis team. Prior to joining
Arcutis, Mr. Madan served as the Vice President of Digital,
Data/Analytics and Innovation for Consumer Healthcare Technology at
GlaxoSmithKline (GSK), where in partnership with the Chief Digital
Officer, he was responsible for driving significant elements of
their digital and tech transformation globally. Before GSK, Mr.
Madan was with Novartis where he was responsible for managing and
delivering global, regional and localized digital solutions and
services across three business units and in more than 80 countries.
In addition to healthcare, Mr. Madan has experience in the consumer
goods sector, having spent 14 years at L’Oreal in various roles,
including managing the Digital Tech function for L’Oreal Americas.
Mr. Madan holds a bachelor’s degree in computer engineering from
the New Jersey Institute of Technology and master’s degrees in both
business administration and information systems from New York
University Stern School of Business.About
ArcutisArcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a
late-stage biopharmaceutical company focused on developing and
commercializing treatments for unmet needs in immune-mediated
dermatological diseases and conditions, or immuno-dermatology. The
company is leveraging recent advances in immunology and
inflammation to develop differentiated therapies against
biologically validated targets to solve persistent treatment
challenges in serious diseases of the skin. Arcutis’
robust pipeline includes four novel drug candidates
currently in development for a range of inflammatory dermatological
conditions. The company’s lead product candidate, topical
roflumilast, has the potential to revitalize the standard of care
for plaque psoriasis, atopic dermatitis, scalp psoriasis, and
seborrheic dermatitis. For more information,
visit www.arcutis.com or follow the company
on LinkedIn and Twitter.
Forward-Looking StatementsThis press release
contains "forward-looking" statements, including, among others,
statements regarding the potential for roflumilast to revolutionize
the standard of care in plaque psoriasis and other inflammatory
dermatological conditions. These statements involve substantial
known and unknown risks, uncertainties and other factors that may
cause our actual results, levels of activity, performance, or
achievements to be materially different from the information
expressed or implied by these forward-looking statements and you
should not place undue reliance on our forward-looking statements.
Risks and uncertainties that may cause our actual results to differ
include risks inherent in the clinical development process and
regulatory approval process, the timing of regulatory filings, and
our ability to defend our intellectual property. For a further
description of the risks and uncertainties applicable to our
business, see the "Risk Factors" section of our Form 10-K filed
with U.S. Securities and Exchange Commission (SEC) on February 16,
2021, as well as any subsequent filings with the SEC. We undertake
no obligation to revise or update information herein to reflect
events or circumstances in the future, even if new information
becomes available.
Investor and Media Contact:ir@arcutis.com
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Sep 2023 to Sep 2024